Ansquer, Jean-Claude

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 264

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Drury, P. L., Ting, R., Zannino, D., Ehnholm, C., Flack, J., Whiting, M., Fassett, R., Ansquer, J.-C., Dixon, P., Davis, T. M. E., et al. (2011) · Diabetologia

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 195

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

Ansquer, J.-C., Dalton, R. N., Caussé, E., Crimet, D., Le Malicot, K., & Foucher, C. (2008) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 107

Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study

Ansquer, J., Foucher, C., Aubonnet, P., & Le Malicot, K. (2009) · Current Pharmaceutical Design

Retinal Diseases and TreatmentsChronic Kidney Disease and Diabetes

Cited by 72

Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes

Vakkilainen, J., Steiner, G., Ansquer, J.-C., Perttunen-Nio, H., & Taskinen, M.-R. (2002) · Diabetes Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 40